Saturday 17 October 2026 Export CASIF’s income statement to Excel — free account

CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.7 million, down 27.4% from fiscal 2024. In the quarter to December 2025, revenue fell 45.9%, EPS grew 54.4%, free cash flow fell 23,251.7% and total debt rose 6.97%, each against the same quarter a year earlier.

0.10 0.00 0.00%

Follow CASIF

Alert me

Market cap: $12.4M
P/E: 0.0×
Fwd P/E: −0.1×
Dividend yield: —
F-score: 4/9
Altman Z: −47.08
Beneish M: −8.73
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 89.10%

Capital & Financial Ratios $m

Market Cap 12.39

Revenue 20.71

Net Income (31.86)

Free Cash Flow (70.46)

Net Debt 16.02

Current Ratio 0.15

Debt/Equity (0.34)

P/E ratio 0.00

Fwd P/E (0.09)

P/S ratio 0.09

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (0.78%)

Next Y EPS Growth 45.35%

Next Y revenue growth (34.87%)

Next 5Y EPS Growth 18.42%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.18%

10-year low 10-year high

EV/Sales against its own 10 years 16.35%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	31	16	6	4
Receivables	10	15	4	3
Inventory	16	5	2	2
Other	—	—	—	—
	59	40	13	10

	2023	2024	2025	Q'26
Payables	4	3	1	1
ST’ Debt	—	18	23	20
Other	—	—	1	1
	17	36	50	67

Compound Annual Growth %

	10y	5y	3y
Sales	—	6.47%	(21.68%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	6	4	3	7	21
’24	3	4	8	13	29
’23	8	10	9	7	34
’22	9	9	10	15	43
’21	6	7	8	9	30
’20	3	3	4	5	15

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	(21)	(21)
’24	—	(18)	—	(29)	(29)
’23	—	—	—	—	(20)
’22	(4)	(9)	(7)	(1)	(21)
’21	(8)	(7)	(4)	(8)	(27)
’20	(5)	(6)	(7)	(8)	(26)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	(21)	(21)
’24	—	(18)	—	(29)	(29)
’23	—	0	—	(2)	(22)
’22	(7)	(9)	(7)	(4)	(27)
’21	(9)	(8)	(6)	(13)	(36)
’20	(4)	(6)	(6)	(8)	(25)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	(0.69)	(0.86)	(0.67)	(0.36)	(2.59)
’24	(0.71)	(0.52)	(0.55)	(0.79)	(2.56)
’23	(0.45)	(0.77)	(0.35)	(0.45)	(2.02)
’22	(0.60)	(0.56)	(0.38)	(1.44)	(3.01)
’21	(1.10)	(0.50)	(0.70)	(0.40)	(2.70)
’20	(0.90)	(0.90)	(1.40)	(1.20)	(4.40)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5.80	9.10	27.30	28.30	11.50	7.50	1.45	1.60	2.05	0.75	Analyst estimates 2026–2028 Powerpack
	High	17.60	48.40	88.90	41.90	33.20	39.00	10.30	8.48	8.19	3.29
People
People	Employees	27	51	125	125	144	176	224	243	233	214
	Revenue/emp, $m	0.00	0.00	0.00	0.03	0.11	0.17	0.19	0.14	0.12	0.10
Income, $m
Income, $m	Revenue	—	—	—	4	15	30	43	34	29	21
	Gross margin, %	0.00	0.00	0.00	4.74	37.20	58.38	63.28	59.19	39.06	48.65
	EBT	(9)	(11)	(27)	(45)	(48)	(36)	(37)	(26)	(38)	(46)
	EBT margin, %	0.00	0.00	0.00	(1,098.09)	(313.79)	(118.81)	(86.83)	(77.61)	(133.40)	(221.47)
	Net income	(9)	(11)	(27)	(45)	(48)	(36)	(40)	(26)	(39)	(48)
	Depreciation	0	0	2	2	2	2	2	4	2	1
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.43	1.37	2.22	3.16	2.54	1.86	1.12
	Earnings	(1.70)	(1.80)	(3.20)	(4.80)	(4.40)	(2.70)	(3.01)	(2.02)	(2.56)	(2.59)
	Cash flow	(1.08)	(1.04)	(3.37)	(2.42)	(2.34)	(1.97)	(1.55)	(1.49)	(1.91)	(1.12)
	Capex	(0.01)	(0.15)	(0.13)	(0.04)	0.11	(0.66)	(0.40)	(0.17)	0.02	0.00
	Free cash flow	(1.09)	(1.19)	(3.51)	(2.47)	(2.23)	(2.63)	(1.95)	(1.66)	(1.89)	(1.12)
	Book value	3.72	6.27	12.92	7.61	7.38	6.21	3.27	1.81	0.12	(2.01)
	Shares, m	6	6	8	10	11	14	14	13	15	19
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	71.35	21.52	3.61	0.58	2.85	1.52	0.76
	P/B	—	—	—	4.06	4.00	1.29	0.56	3.99	23.45	0.00
	EV/Sales	—	—	—	58.83	17.25	2.11	(0.50)	2.61	2.27	2.54
	EV/FCF	—	—	—	(10.33)	(10.58)	(1.83)	0.82	(1.90)	(1.15)	(0.75)
Cash, $m
Cash, $m	Operating cash flow	(6)	(6)	(29)	(23)	(26)	(27)	(21)	(20)	(29)	(21)
	Capex	0	(1)	(1)	0	1	(9)	(5)	(2)	0	0
	Free cash flow	(6)	(7)	(30)	(24)	(25)	(36)	(27)	(22)	(29)	(21)
Balance, $m
Balance, $m	Working capital	26	39	89	57	66	49	56	43	3	(36)
	Total debt	1	1	1	2	2	3	—	19	18	23
	Net debt	(26)	(42)	(84)	(52)	(65)	(45)	(51)	(12)	2	18
	Shareholders’ equity	21	39	109	73	82	85	45	24	2	(37)
Returns, %
Returns, %	ROA	(56.37)	(29.58)	(34.66)	(42.61)	(41.92)	(27.56)	(34.98)	(31.44)	(60.89)	(121.17)
	ROIC	0.00	0.00	(65.75)	(140.09)	(194.53)	(66.19)	0.00	(127.53)	(591.25)	0.00
	ROE	(128.65)	(36.31)	(37.12)	(50.46)	(62.49)	(44.15)	(63.55)	(78.44)	(301.80)	271.28

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ALLR Allarity Therapeutics, Inc.	$13.2M	— (loss-making)	— (loss-making)	—	n/m	+53.22% (above 0%: growing)	100.00%	0.00%	Compare
CTXR Citius Pharmaceuticals, Inc.	$12.6M	— (loss-making)	—	—	n/m	−60.50% (below 0%: shrinking)	67.07%	(785.39%)	Compare
CASIF CASI Pharmaceuticals Inc.	$12.4M	— (loss-making)	— (loss-making)	−45.93% (below 0%: shrinking)	n/m	−23,251.69% (below 0%: shrinking)	51.14%	(147.67%)
AEON AEON Biopharma, Inc.	$12.1M	— (loss-making)	—	—	n/m	−76.85% (below 0%: shrinking)	—	0.00%	Compare
ASBP Aspire-Lakewood Holdings, Inc.	$12.1M	0.2×	—	—	n/m	−85.54% (below 0%: shrinking)	(47.70%)	(4,244.37%)	Compare
ACTU Actuate Therapeutics, Inc.	$12.0M	— (loss-making)	—	—	n/m	−5.54% (below 0%: shrinking)	—	0.00%	Compare
PLUR Pluri Inc.	$11.9M	— (loss-making)	— (loss-making)	−15.83% (below 0%: shrinking)	n/m	+25.03% (above 0%: growing)	58.51%	(1,655.52%)	Compare
INAB IN8bio, Inc.	$11.7M	— (loss-making)	—	—	n/m	−1.30% (below 0%: shrinking)	0.00%	0.00%	Compare
ENSC Ensysce Biosciences, Inc.	$11.6M	— (loss-making)	— (loss-making)	−15.10% (below 0%: shrinking)	n/m	+27.50% (above 0%: growing)	100.00%	(221.28%)	Compare
Median of peers	$12.1M	—	—	—	—	−3.42%	62.79%	(110.64%)

All 614 Biotechnology stocks →

CASI Pharmaceuticals Inc. (CASIF) key facts

Concern: CASI Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.7 million, down 27.4% from fiscal 2024.
CASI Pharmaceuticals Inc. (CASIF) is a Biotechnology company in the Healthcare sector.
As of October 16, 2026, CASIF traded at $0.10, a market capitalization of $12.4 million.
Return on equity was 271.3% and debt-to-equity -0.34.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −47.08 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.